| |

Mesothelioma Multidisciplinary Team Improves Patient Outcomes

ByHolly Zink
Localized Mesothelioma Successfully Treated with Chemotherapy and Surgery

Oxford University Hospital found that a multidisciplinary team is best in mesothelioma care.

This treatment approach includes many doctors who are experts in different specialties. Together, they offer the best clinical decision-making team, and they improve patient outcomes.

There are many factors that impact clinical decision-making. But this new report focuses on which factors improve mesothelioma patient care. And which factors support informed decisions about follow-up care.

Results showed that the most important factor is a strong team of doctors.

Two Heads are Better than One

Malignant pleural mesothelioma is a rare, incurable cancer coming from asbestos exposure. Patients have a poor prognosis and a median survival rate of 8 to 14 months.

Differences in mesothelioma clinical decision-making are common. One doctor may give different advice than another. There is also often a lack of knowledge sharing between clinics.

Even at the same hospital, a patient may get conflicting advice. This can lead to conflicts in treatment decisions.

We don’t know a lot about factors that affect clinicians’ decision-making in mesothelioma. But this is key to ensuring that mesothelioma patients get the best advice and support.

And this is the question that Oxford researchers wanted to answer.

Researchers found something interesting about how clinicians conduct team meetings. They found that a multidisciplinary team structure works best for mesothelioma.

Multidisciplinary teams are a popular model of health care delivery. They offer patients managed care services from different specialists. Many doctors come together to diagnose problems early and develop cohesive treatment plans.

A multidisciplinary team improves mesothelioma outcomes. Clinicians are better supported in this setting. And patients are better informed.

Using Multidisciplinary Teams to Optimize Patient Care

Healthcare professionals should always consider a multidisciplinary team structure for mesothelioma. Policymakers are also encouraged to consider this approach.

A multidisciplinary team ensures that patients are reviewed by clinicians with appropriate expertise. This team of experts shares an understanding of how, why, and when decisions should be made. Together, this team of mesothelioma experts can act to achieve optimal patient care outcomes.

Source:

Henshall, C., Dawson, P., Rahman, N., Ball, H., Sundralingam, A., Shahidi, M., McKeown, E., Park, J., Walthall, H. and Davey, Z., 2022. Understanding clinical decision-making in mesothelioma care: a mixed methods study. BMJ Open Respiratory Research, 9(1), p.e001312. https://bmjopenrespres.bmj.com/content/9/1/e001312.abstract

Similar Posts

  • |

    Mesothelioma Still Rising Despite Ban in Ireland

    ByAlex Strauss

    A study in Ireland confirms that it can take many years for a ban on asbestos to have a measurable impact on a country’s rates of malignant mesothelioma. Mesothelioma is the most serious of a list of diseases – including lung cancer, pleural plaques, asbestosis, and others – linked with exposure to asbestos dust. Affecting the linings around the lungs and other organs, mesothelioma is often resistant to most cancer treatments and may be fatal within a year of diagnosis. According to the International Ban Asbestos Secretariat, Ireland is one of 55 countries that have enacted some type of asbestos ban. However, although Ireland banned asbestos in 2000, a new study published in Cancer Epidemiology shows that incidence of the…

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    ByAlex Strauss

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…

  • | |

    Spanish Mesothelioma Deaths Likely to Continue for Decades

    ByAlex Strauss

    New research in Spain suggests that mesothelioma deaths will continue in the country until the “last surviving member” of the group of people exposed to occupational asbestos succumbs to the disease. Like many countries, Spain used asbestos heavily in the first half of the 20th century, especially in construction, where the mineral was prized for its durability, low cost, and resistance to fire and corrosion.  Asbestos was banned in Spain in 2002. Observing that more than 2.5 million metric tons of asbestos were imported into Spain from 1906 to 2002, researchers say deaths from mesothelioma have risen steadily. Between 1976 and 1980, a total of 491 Spanish people died of mesothelioma. By the 5-year period from 2006 to 2010, that…

  • | |

    Micro-RNAs May Offer New Way to Fight Mesothelioma

    ByAlex Strauss

    Scientists at one of the world’s top mesothelioma research centers, the Asbestos Diseases Research institute in Sydney, Australia, say that restoring the expression of certain micro RNAs in the cells of mesothelioma patients may offer a new way to fight the disease. A microRNA is a small RNA molecule which is involved in the regulation of gene expression. According to a new report in the Annals of Oncology, the Australian scientists found reduced expression of the micro RNA-15 family (miR-15/16) in the cells of mice with mesothelioma. “When malignant pleural mesothelioma cell lines were compared with the normal mesothelial cell line MeT-5A, the downregulation of miR-15/16 was 2- to 10-fold,” they report. This finding is consistent with previous cancer research…

  • | |

    Treatment Uses Herpes Virus to Shrink Mesothelioma Tumors

    ByAlex Strauss

    Researchers at a hospital in Sheffield, England are testing a potential new mesothelioma treatment based on the same virus that causes herpes. The small-scale trial is the first in the world to test the modified herpes simplex virus, HSV1716, in human mesothelioma patients. HSV1716 has been genetically engineered to infect and kill cancer cells without harming healthy cells. In laboratory studies on mesothelioma and some other cancers, it has been shown to be effective at shrinking tumors while causing limited toxicity. Just as significantly, HSV1716 increased survival rates among mice with various human cancers. The Phase I/II trial at Sheffield Experimental Cancer Medicine Centre is the next stage in development of HSV1716 as a viable mesothelioma treatment. The goal of…

  • | |

    New Mesothelioma Drug Kills Cancer Stem Cells

    ByAlex Strauss

    Citing “significant enthusiasm within the mesothelioma community”, the manufacturers of a promising new mesothelioma drug say they have begun a major test of the drug in patients. Massachusetts-based Verastem, Inc. focuses on drugs that fight cancer by attacking the stem cells that give rise to them. Earlier this summer, the FDA granted orphan drug status to their stem cell inhibitor, defactinib, for the treatment of mesothelioma. The designation, which is reserved for drugs that fight the rarest of diseases, helps pave the way for testing and faster approval, depending on the results of clinical trials. “Development of a drug that preferentially kills cancer stem cells is a promising approach, as many standard-of-care treatments have been shown to either have no…